| Description |
This is a Phase II, open label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in patients with advanced thymic carcinoma who failed prior systemic therapy. The study will consist of a screening period (Day-28 to -1), a treatment period, a treatment discontinuation visit occuring <= 30 days after the last dose of atezolizumab and a 24-month survival follow-up period. Day 1(baseline) will be defined as the first day a patient receives atezolizumab. It is anticipated that the trial will enroll 34 patients at 10 sites in China. |
